COMET-1 study stays course, Exelixis falls on investor hopes
This article was originally published in Scrip
Exelixis shares took a beating on 26 March based on an interim review of the Phase III COMET-1 clinical trial for Cometriq (cabozantinib) in the treatment of metastatic castrate-resistant prostate cancer (mCPRC), but not because the analysis revealed a specific safety or efficacy concern.
You may also be interested in...
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.